Endourological Management of Stones During COVID19
Definitive Endourological Interventions for Urolithiasis Management During COVID19- Outcomes From a Cohort Study
Guidelines for endourological procedures during COVID-19 have suggested deferring all elective procedures, while obstructed/ infected stones should undergo urgent decompression.
At our centre, screening protocols were implemented with prioritization strategies so that elective care could safely continue at deescalated rates. COVID or septic patients underwent emergency decompression, while non-COVID and non-septic patients underwent primary ureteroscopy (URS) or retrograde intrarenal surgery (RIRS).
We aim to report our experience with endourological surgery for stone disease during COVID-19.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Singapore, Singapore, 609606
- Ng Teng Fong General Hospital, Singapore
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion criteria
- all patient with urolithiasis who underwent endourological interventions during COVID19 pandemic
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Patients who underwent endourological surgery for urolithiasis during COVID19
Endourological surgery (including ureteral stent insertion, ureteroscopy, retrograde intrarenal surgery)
|
Includes ureteral stent insertion, ureteroscopies and retrograde intrarenal surgeies
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Length of hospital stay
Time Frame: From admission to discharge from hospital, up to 3 months
|
Length of hospital stay
|
From admission to discharge from hospital, up to 3 months
|
|
Complication rate
Time Frame: From admission up to 3 months post operatively
|
Complications as defined by Clavien Dindo classification system
|
From admission up to 3 months post operatively
|
|
Stone free rate
Time Frame: At follow up visit in clinic 3 months post procedure
|
At follow up visit in clinic 3 months post procedure
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Readmission rate
Time Frame: From discharge up to three months post operatively
|
From discharge up to three months post operatively
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Chin Tiong Heng, Ng Teng Fong General Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- Urologic Diseases
- Pathological Conditions, Anatomical
- Calculi
- COVID-19
- Urinary Calculi
- Urolithiasis
Other Study ID Numbers
Other Study ID Numbers
- 2020/01298
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
NCT06923137Active, not recruitingCOVID-19 | Coronavirus Disease 2019 (COVID-19) | COVID-19 Infection | COVID-19 Vaccines | SARS-CoV-2 Infection, COVID19 | COVID-19 Vaccination | SARS-CoV-2 Infection, COVID-19 | COVID-19 (Coronavirus Disease 2019) | COVID-19 SARS-CoV-2 Infection
-
NCT06768697Not yet recruiting
-
NCT07110714RecruitingPost COVID-19 Condition | Post COVID-19 | Post COVID-19 Syndrome | Long COVID-19 Syndrome | Post COVID-19 Condition (PCC)
-
NCT07552779RecruitingRespiratory Tract Diseases | COVID-19 | Pneumonia | Lung Diseases | Coronavirus Disease 2019 | Coronavirus Disease 2019 (COVID-19) | COVID-19 Infection | Upper Respiratory Tract Infections | Respiratory Tract Infection | COVID-19 (Coronavirus Disease 2019)
-
NCT07445971RecruitingCOVID -19 | COVID-19 (Prevention)
-
NCT06156176RecruitingFatigue | Post-COVID-19 Syndrome | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19 | Long-COVID | Post-COVID Condition
-
NCT06294756CompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 Syndrome
-
NCT05839236Active, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated Stroke
-
NCT05817032RecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19
Clinical Trials on Endourological surgery
-
NCT04152369UnknownAsymptomatic Bacteriuria | Antimicrobial Prophylaxis
-
NCT04866147CompletedAcute Post Operative Pain | Chronic Postsurgical Pain
-
NCT02325453Unknown
-
NCT02125929CompletedPancreatic Neuroendocrine Tumors
-
NCT06290960Enrolling by invitationRectal Cancer | PROM | Functional Bowel Disorder
-
NCT07622758Completed
-
NCT02451384UnknownCarcinoma, Pancreatic Ductal | Circulating Tumor Cells
-
NCT05270616RecruitingLung Diseases | Surgery
-
NCT01470378UnknownObesity | Lymphedema